Swietenine Alleviates Nonalcoholic Fatty Liver Disease in Diabetic Mice via Lipogenesis Inhibition and Antioxidant Mechanisms

Our previous studies have reported the effect of swietenine (a major bioactive component of Swietenia macrophylla seeds) in reversing and potentiating the effect of metformin in hyperglycemia and hyperlipidaemia in diabetic rats. Moreover, we reported that the anti-inflammatory effect of swietenine is mediated via the activation of nuclear factor erythroid 2-related factor 2 (Nrf2). This study evaluated the effect of swietenine and its mechanisms in nonalcoholic fatty liver disease (NAFLD) in high-fat diet/streptozotocin-induced diabetic mice. The effect was assessed by determining blood biochemical parameters (glucose, cholesterol, triglycerides, alanine transaminase (ALT), asparate transaminase (AST), alkaline phosphatase (ALP), glutathione (GSH), total antioxidant capacity (TAC), and malondialdehyde (MDA)) and liver biochemical parameters (liver index, cholesterol, and triglycerides). Hepatic lipid accumulation (initial causative factor in NAFLD) was determined by oil-O-red staining. Gene expression (qPCR) and immunohistochemical studies were performed to elucidate the mechanism of swietenine’s effect in NAFLD. The critical regulators (genes and proteins) involved in lipogenesis (ACLY, ACC1, FASN, SREBP1c, and ChREBPβ) and oxidative stress (Nrf2, NQO-1 and HO-1) pathways were determined. In mice fed with a high-fat diet followed by streptozotocin injection, the liver cholesterol, triglycerides, and lipids were elevated. These increases were reversed by the oral administration of swietenine, 80 mg/kg body weight, on alternate days for eight weeks. Gene expression and immunohistochemical studies showed that swietenine reversed the elevated levels of crucial enzymes of lipogenesis (ACLY, ACC1 and FASN) and their master transcription factors (SREBP1c and ChREBPβ). Furthermore, swietenine activated the Nrf2 antioxidant defense mechanism, as evidenced by the upregulated levels of Nrf2, NQO-1, and HO-1. It is concluded that swietenine shows beneficial effects in diabetes-induced NAFLD via inhibiting lipogenesis and activating the Nrf2 pathway.

[1]  J. Hayes,et al.  Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2. , 2022, Free radical biology & medicine.

[2]  A. Duseja,et al.  Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena , 2022, Liver Research.

[3]  Stephen L. Pinkosky,et al.  Lipogenesis inhibitors: therapeutic opportunities and challenges , 2022, Nature Reviews Drug Discovery.

[4]  John G. Jones,et al.  De novo lipogenesis in non‐alcoholic fatty liver disease: Quantification with stable isotope tracers , 2021, European journal of clinical investigation.

[5]  L. Poretsky,et al.  Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD) , 2021, Metabolism open.

[6]  M. Mohamed,et al.  The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: molecular targets , 2021, Archives of physiology and biochemistry.

[7]  S. De Martin,et al.  The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases , 2021, Biomedicines.

[8]  I. Rowe,et al.  A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD , 2021, Hepatology.

[9]  Kit-Kay Mak,et al.  Swietenine potentiates the antihyperglycemic and antioxidant activity of Metformin in Streptozotocin induced diabetic rats. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  P. Vajro,et al.  Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review , 2021, Frontiers in Medicine.

[11]  A. Dinkova-Kostova,et al.  Studies on the mechanism of anti-inflammatory action of swietenine, a tetranortriterpenoid isolated from Swietenia macrophylla seeds , 2021 .

[12]  J. C. Arroyave-Ospina,et al.  Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy , 2021, Antioxidants.

[13]  M. Tatham,et al.  Downregulation of Keap1 Confers Features of a Fasted Metabolic State , 2020, iScience.

[14]  B. Staels,et al.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease , 2020, Molecular metabolism.

[15]  Jibiao Wu,et al.  An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease , 2020, BioMed research international.

[16]  X. Ci,et al.  The Role of Nrf2 in Acute Kidney Injury: Novel Molecular Mechanisms and Therapeutic Approaches. , 2020, Free radical biology & medicine.

[17]  S. Bakker,et al.  Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[18]  O. Hamdy,et al.  Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? , 2020, Clinical Diabetes and Endocrinology.

[19]  A. Chowdhury,et al.  Epidemiology of non-alcoholic and alcoholic fatty liver diseases. , 2020, Translational gastroenterology and hepatology.

[20]  Hongliang Li,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. , 2020, Free radical biology & medicine.

[21]  Sukardiman,et al.  The recent use of Swietenia mahagoni (L.) Jacq. as antidiabetes type 2 phytomedicine: A systematic review , 2020, Heliyon.

[22]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[23]  J. Morales-González,et al.  NRF-2 and nonalcoholic fatty liver disease. , 2020, Annals of hepatology.

[24]  Wei Yue,et al.  Semi-quantitative Determination of Protein Expression using Immunohistochemistry Staining and Analysis: An Integrated Protocol. , 2019, Bio-protocol.

[25]  G. Jena,et al.  NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[26]  P Janhavi,et al.  DoseCal: a virtual calculator for dosage conversion between human and different animal species , 2019, Archives of physiology and biochemistry.

[27]  H. Kuivaniemi,et al.  Pharmacological inhibition of Notch signaling regresses pre-established abdominal aortic aneurysm , 2019, Scientific Reports.

[28]  C. Semenkovich,et al.  Circulating serum fatty acid synthase is elevated in patients with diabetes and carotid artery stenosis and is LDL-associated. , 2019, Atherosclerosis.

[29]  Ipek Süntar.  Importance of ethnopharmacological studies in drug discovery: role of medicinal plants , 2019, Phytochemistry Reviews.

[30]  A. Shevchenko,et al.  Acetyl-CoA carboxylase 1–dependent lipogenesis promotes autophagy downstream of AMPK , 2019, The Journal of Biological Chemistry.

[31]  Xin Gao,et al.  Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease , 2019, The Journal of Biological Chemistry.

[32]  V. Wong,et al.  Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. , 2019, The lancet. Gastroenterology & hepatology.

[33]  G. Su,et al.  Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? , 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[34]  Y. Liu,et al.  Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues , 2019, Front. Pharmacol..

[35]  Hailong Wu,et al.  The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches , 2019, Front. Pharmacol..

[36]  P. Muti,et al.  Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. , 2019, Cell metabolism.

[37]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[38]  A. Ore,et al.  Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease , 2018, Medicina.

[39]  G. Svegliati-Baroni,et al.  Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.

[40]  C. Celsa,et al.  Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? , 2018, Pharmaceuticals.

[41]  F. Bessone,et al.  Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.

[42]  A. Federico,et al.  Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease , 2018, Oxidative medicine and cellular longevity.

[43]  D. Harrison,et al.  Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2) , 2017, Cellular and molecular gastroenterology and hepatology.

[44]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[45]  Manisha Pandey,et al.  An update on natural compounds in the remedy of diabetes mellitus: A systematic review , 2017, Journal of traditional and complementary medicine.

[46]  M. Alves-Bezerra,et al.  Triglyceride Metabolism in the Liver. , 2017, Comprehensive Physiology.

[47]  Vincent Wai-Sun Wong,et al.  New trends on obesity and NAFLD in Asia. , 2017, Journal of hepatology.

[48]  L. Vonghia,et al.  Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide , 2017, Nutrients.

[49]  M. Yuen,et al.  Nonalcoholic fatty liver disease in Asia: emerging perspectives , 2017, Journal of Gastroenterology.

[50]  Chan-Sik Park,et al.  Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips , 2016, Journal of pathology and translational medicine.

[51]  M. Charlton,et al.  The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health , 2016, Hepatology.

[52]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[53]  L. Henry,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. , 2016, Clinics in liver disease.

[54]  S. Koo,et al.  Regulation of glucose metabolism from a liver-centric perspective , 2016, Experimental & Molecular Medicine.

[55]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[56]  Masayuki Yamamoto,et al.  Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. , 2016, Archives of biochemistry and biophysics.

[57]  Ning Wang,et al.  The Role of Oxidative Stress and Antioxidants in Liver Diseases , 2015, International journal of molecular sciences.

[58]  Q. Anstee,et al.  Nonalcoholic fatty liver disease: new treatments , 2015, Current opinion in gastroenterology.

[59]  J. Osorio.  Diabetes: Hepatic lipogenesis independent of insulin in type 2 diabetes mellitus—a paradox clarified , 2015, Nature Reviews Endocrinology.

[60]  M. Pichika,et al.  Acute oral toxicity studies of Swietenia macrophylla seeds in Sprague Dawley rats , 2015, Pharmacognosy research.

[61]  Ying Zhang,et al.  Nrf2 affects the efficiency of mitochondrial fatty acid oxidation. , 2014, The Biochemical journal.

[62]  Ann-Hwee Lee,et al.  Transcriptional Control of Hepatic Lipid Metabolism by SREBP and ChREBP , 2013, Seminars in Liver Disease.

[63]  Soheil Zorofchian Moghadamtousi,et al.  Biological Activities and Phytochemicals of Swietenia macrophylla King , 2013, Molecules.

[64]  C. P. Lim,et al.  Anti-hyperglycaemic activity of swietenia macrophylla king (meliaceae) seed extracts in normoglycaemic rats undergoing glucose tolerance tests , 2013, Chinese Medicine.

[65]  U. Raychaudhuri,et al.  Antidiabetic and antioxidant effect of Swietenia macrophylla seeds in experimental type 2 diabetic rats , 2013, International Journal of Diabetes in Developing Countries.

[66]  J. Manautou,et al.  Nrf2: A Potential Target for New Therapeutics in Liver Disease , 2012, Clinical pharmacology and therapeutics.

[67]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[68]  C. Semenkovich,et al.  Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? , 2012, Biochimica et biophysica acta.

[69]  Yu-Qing Wu,et al.  Enhanced expression of salusin-β contributes to progression of atherosclerosis in LDL receptor deficient mice. , 2012, Canadian journal of physiology and pharmacology.

[70]  A. Papavassiliou,et al.  Nrf2 Represses FGF21 During Long-Term High-Fat Diet–Induced Obesity in Mice , 2011, Diabetes.

[71]  M. Sporn,et al.  Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. , 2009, European journal of pharmacology.

[72]  S. Mandal,et al.  Evaluation of antidiabetic activity of the seeds of Swietenia macrophylla in diabetic rats , 2009 .

[73]  C. Klaassen,et al.  NF-E2-Related Factor 2 Inhibits Lipid Accumulation and Oxidative Stress in Mice Fed a High-Fat Diet , 2008, Journal of Pharmacology and Experimental Therapeutics.

[74]  J. Girard,et al.  Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. , 2005, Biochimie.

[75]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[76]  E. Schenk,et al.  Oil red O: comparison of staining quality and chemical components as determined by thin layer chromatography. , 1986, Stain technology.